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Background: A limiting factor in performing proteomics analysis on cancerous cells is the difficulty in obtaining
sufficient amounts of starting material. Cell lines can be used as a simplified model system for studying changes
that accompany tumorigenesis. This study used two-dimensional gel electrophoresis (2DE) to compare the whole
cell proteome of oral cancer cell lines vs normal cells in an attempt to identify cancer associated proteins.
Results: Three primary cell cultures of normal cells with a limited lifespan without hTERT immortalization have been
successfully established. 2DE was used to compare the whole cell proteome of these cells with that of three oral
cancer cell lines. Twenty four protein spots were found to have changed in abundance. MALDI TOF/TOF was then
used to determine the identity of these proteins. Identified proteins were classified into seven functional
categories – structural proteins, enzymes, regulatory proteins, chaperones and others. IPA core analysis predicted that
18 proteins were related to cancer with involvements in hyperplasia, metastasis, invasion, growth and tumorigenesis.
The mRNA expressions of two proteins – 14-3-3 protein sigma and Stress-induced-phosphoprotein 1 – were found to
correlate with the corresponding proteins’ abundance.
Conclusions: The outcome of this analysis demonstrated that a comparative study of whole cell proteome of cancer
versus normal cell lines can be used to identify cancer associated proteins.
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Oral cancer is a devastating disease that ranks as the
fifth most common type of cancer affecting humans
worldwide [1]. Incidence and mortality rates vary widely
across the world. There are approximately 500,000 new
oral and pharyngeal cancer cases diagnosed annually,
with three quarters being registered in developing coun-
tries [2,3]. The disease is highly associated with estab-
lished cultural risk factors such as tobacco chewing/
smoking, alcohol consumption and betel-quid chewing
[4]. In western countries, cigarette smoking and alcohol
drinking are the major risk factors while betel-quid
chewing and smoking are the major risk factors that* Correspondence: saiful72@um.edu.my
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reproduction in any medium, provided the orcontribute to the development of oral cancer in South
Asia, Southeast Asia and Taiwan [1]. Oral cancer ap-
pears as an abnormal growth within the mouth region
and this include the buccal mucosa (cheek), tongue,
floor of the mouth and lip. Oral squamous cell carcin-
oma (OSCC) represents the highest of all oral malig-
nancy, accounting for more than 95% of total cases
reported [1,3].
There is a dearth of knowledge with regards to the
development and progression of oral cancer. The exact
molecular mechanisms remain unknown. However, it is
known to involve the activation of oncogenes, change in
expression of various proteins which would eventually
lead to the development of cancer. Thus, a study of
proteins that change in oral cancer will provide valuable
information and add to our understanding of the disease.
It may also identify candidate proteins that can potentially
be utilized as biomarkers for early detection. The ability of
proteomics to compare differences/changes in proteomeLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tions) which are related to tumor progression has been
adapted in clinical research for the identification of bio-
markers for disease such as cancer [5].
One of the main problems in performing proteomics
analysis on cancerous cells is the difficulty in obtaining
sufficient amounts of material to perform the analysis.
The availability of cancer cell lines makes it possible to
obtain an almost limitless amount of sample for prote-
omic analysis. Cultured cancer and normal cell lines
can be used as a simplified model system for studying
changes that accompany tumorigenesis. Thus, this study
aims to utilize proteomics in identifying differences be-
tween proteome profiles of normal primary cultures vs
oral cancer cell lines. Our results showed that such an
analysis will identify cancer associated proteins.
Results and discussions
Identification of proteins with different abundance
between normal primary cultures and cancer cell lines
More than 1000 individual protein spots were resolved
and visualized on silver stained gels. A representative gel
is shown in Figure 1. Image analysis identified 24 pro-
tein spots that exhibited significant difference in abun-
dance (p < 0.05). All 24 were unambiguously identified
by MALDI-TOF/TOF MS and their respective identities
are shown in Table 1. The index numbers in Table 1
correspond to the numbers in Figure 1 and they indicate
the location of the proteins on the 2DE gels. From thisFigure 1 Representative 2DE gel of whole cell proteome of cell lines.
were resolved by 2DE pI 4–7, 11% second dimension polyacrylamide gel. P
numbers correspond to Spot Number in Table 1.point forward, proteins will be referred to by their abbrevi-
ated names as shown in Table 1. Table 1 includes zoomed
images for all protein spots. The identified proteins were
classified into seven functional categories – structural pro-
teins, enzymes, regulatory proteins, chaperones and others.
For almost all identified proteins, the experimental and
theoretical pI and molecular weights were matched.
When proteins with different abundance in oral cancer
were subjected to analysis using IPA, 18 were predicted to
be related to cancer with involvements in hyperplasia, me-
tastasis, invasion, growth and tumorigenesis. Table 2 shows
a list of proteins known to have roles in various cancers
based on IPA. Figure 2 shows a graphical representation of
the predicted molecular relationships between these pro-
teins. The predicted network involved interplay between
the various proteins and suggested that changes in abun-
dance of these proteins may influence the function of other
proteins within the network. IPA also predicted that most
of the proteins were of cytosolic origin.
Coordinate regulation of proteins with similar function
Two groups of proteins - detoxification enzymes and prote-
asome activator complex - appeared to show coordinate
change in protein abundance in oral cancer.
Detoxification enzymes
Four enzymes involved in the protection of cells
against oxidative stress - Lactoylglutathione lyase
(LGUL), Peroxiredoxin-4 (PRDX4), Glutathione S-The whole cell protein of normal primary cultures and cancer cell lines
roteins with different abundance are shown as numbered spots. The
Table 1 List of proteins with different abundance in cancer cell lines
Protein name Ascension number
(Swissprot)/matched
2D coordinates
MW/pI Peptides
(% cov)
Relative change
vs normal
Zoomed in gel image showing
representative spots
Abbreviation (World-2DPAGE portal)
Theory Experimental Normal Cancer
Structural
20 Stathmin (Phosphoprotein p19) P16949 /SPOT 2D-001YH8 17.3/5.76 >15.0/5.7 4 (18%) +1.6
STMN1
1 Tropomyosin alpha-3 chain
(Tropomyosin-3)
P06753 / 32.8/4.68 >30.0/4.6 6 (13%) −1.5
SPOT 2D-001EM1
SPOT 2D-001YBH
TPM3 SPOT 2D-001JNO
4 Myosin regulatory light chain-2 P19105 / 19.8/4.67 >15.0/4.60 5 (17%) −1.9
SPOT 2D-001JUH
ML12A SPOT 2D-001JUS
Enzymes
6 Lactoylglutathione lyase
(Glyoxalase I). (EC 4.4.1.5)
Q04760 / 20.8/5.12 >20.0/5.00 10 (22%) +7.7
LGUL n/a
24 Triosephosphate isomerase
(EC 5.3.1.1)
P60174 / 26.7/6.45 >25.0/6.5 5 (28%) +2.5
TPIS SPOT 2D-0003MP
18 Nucleoside diphosphate
kinase A (EC 2.7.4.6)
P15531 / 17.1/5.83 >15.0/5.8 8 (31%) +1.5
NDKA n/a
21 Ubiquitin-conjugating
enzyme E2 N
(EC 6.3.2.19)
P61088 / 17.1/6.13 >15.0/5.9 6 (23%) +2.6
UBE2N n/a
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Table 1 List of proteins with different abundance in cancer cell lines (Continued)
16 Gamma-glutamylcyclotransferase
(EC 2.3.2.4)
O75223 / 21.0/5.07 >20.0/5.0 3 (27%) +2.5
GGCT n/a
14 Peroxiredoxin-4
(EC 1.11.1.15)
Q13162 / 30.5/5.86 >30.0/5.8 6 (16%) +2.2
PRDX4 n/a
19 Superoxide dismutase
[Cu-Zn] (EC 1.15.1.1)
P00441 / 15.9/5.70 >15.0/5.70 5 (24%) +1.4
SPOT 2D-001F1V
SODC SPOT 2D-000ZXR
17 Glutathione S-transferase
P (GST class-pi).
(EC 2.5.1.18)
P09211 / 23.3/5.43 >25/5.6 8 (22%) +1.4
SPOT 2D-001EUM
SPOT 2D-0003Q9
GSTP1 SPOT 2D-00085X
11 Proteasome subunit
beta type 4 precursor.
(EC 3.4.25.1)
P28070 / 29.2/5.72 29.0/5.7 6 (15%) +1.6
SPOT 2D-000851
PSB4 SPOT 2D-000D4M
Regulatory proteins
3 14-3-3 protein beta/alpha P31946 / 28.0/4.70 >25.0/4.50 6 (4%) +1.8
1433B n/a
12 Prohibitin P35232 / 29.8/5.57 >25.0/5.60 5 (12%) +1.6
PHB SPOT 2D-001EOL
13 Proteasome activator
complex subunit 1
Q06323 / 28.7/5.78 >25.0/5.70 2 (4%) −1.7
PSME1 SPOT 2D-001YC7
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Table 1 List of proteins with different abundance in cancer cell lines (Continued)
16 Proteasome activator
complex subunit 2
Q9UL46 / 27.3/5.44 >30.0/5.4 4 (11%) −2.3
PSME2 n/a
2 14-3-3 protein
sigma (Stratifin)
P31947 / 27.8/4.68 >25.0/4.50 9 (24%) −2.0
1433S SPOT 2D-001EP6
22 Stress-induced-phosphoprotein 1 P31948 / 62.6/6.4 >55.0/6.50 11 (12%) +2.1
STIP1 n/a
10 Interleukin-1 receptor antagonist
protein precursor
P18510 / 20.0/5.83 >20.0/5.3 2 (8%) +1.3
IL1RA n/a
5 Rho GDP-dissociation
inhibitor 1
P52565 / 23.2/5.02 30.0/5.0 4 (14%) +2.6
GDIR n/a
9 Ran-specific GTPase-activating
protein
P43487 / 23.3/5.19 30/5.2 5 (18%) +1.8
RANG n/a
Chaperones
15 Heat-shock protein
beta-1
P04792 / 22.8/6.00 >20.0/5.8 11 (32%) +3.1
SPOT 2D-001JQI
HSPB1 SPOT 2D-001JQP
23 T-complex protein 1
subunit zeta-2
Q92526 / 57.7/6.63 >55.0/6.8 2 (2%) −1.6
TCPW n/a
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Table 1 List of proteins with different abundance in cancer cell lines (Continued)
Others
8 Chloride intracellular
channel protein 1
(membrane associated)
O00299 / 26.9/5.09 >30.0/5.1 14 (46%) −1.7
CLIC1 SPOT 2D-001YBL
The proteins were grouped into five functional categories – structural proteins, enzymes, regulatory proteins, chaperones and others. The accession number (swiss-prot) and matched 2D coordinates, molecular weight
and pI (theoretical and experimental), number of matched peptides, percentage coverage, relative change vs normal and zoomed in gel image showing representative spots are shown.
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Table 2 Proteins that are known to be cancer associated based on IPA
Category Functions
annotation
p-value Molecules # of
molecules
Cancer Cervical tumor 1.55E-04 GSTP1, HSPB1, PHB, TPM3 4
Cancer Breast cancer 1.82E-04 GGCT, GLO1, GSTP1, NME1, PHB, RANBP1, SOD1, TPI1 8
Cancer Nodular hyperplasia
of liver
1.25E-03 SOD1 1
Cancer Hematological neoplasia 1.89E-03 CCT6B, GSTP1, NME1, PSME1, STIP1, STMN1 6
Cancer Lymphohematopoietic cancer 2.21E-03 CCT6B, GSTP1, NME1, PSME1, STIP1, STMN1 6
Cancer Cervical cancer 2.44E-03 GSTP1, HSPB1, TPM3 3
Cancer Multiplicity of benign tumor 2.50E-03 GSTP1 1
Cancer Neuroblastoma 3.33E-03 GSTP1, NME1 2
Cancer Epidermal hyperplasia 4.24E-03 PHB, RANBP1 2
Cancer Metastasis of melanoma 4.99E-03 IL1RN 1
Cancer Gastric cancer 5.75E-03 GSTP1, IL1RN, PHB 3
Cancer Digestive organ
tumor
6.00E-03 GSTP1, IL1RN, NME1, PHB, SFN, SOD1, STIP1, TPI1 8
Cancer Invasion of trophoblast 7.48E-03 NME1 1
Cancer Urothelial bladder carcinoma 7.48E-03 GSTP1 1
Cancer Non-small cell
lung cancer
7.89E-03 GSTP1, MYL12A, STMN1 3
Cancer Cancer 8.08E-03 CCT6B, GGCT, GLO1, GSTP1, HSPB1, IL1RN, MYL12A, NME1,
PHB, PSME1, RANBP1, SFN, SOD1, STIP1, STMN1, TPI1, TPM3
17
Cancer Liver cancer 9.35E-03 GSTP1, NME1, SOD1, TPI1 4
Cancer Immortalization of keratinocytes 9.96E-03 SFN 1
Cancer Invasion of extracellular matrix 1.12E-02 NME1 1
Cancer Neoplasia of cells 1.21E-02 NME1, PHB, SFN 3
Cancer Hematologic cancer 1.27E-02 GSTP1, NME1, PSME1, STIP1 4
Cancer Hereditary diffuse gastric cancer 1.37E-02 IL1RN 1
Cancer Growth of secondary tumor 1.49E-02 IL1RN 1
Cancer Incidence of hepatocellular carcinoma 1.49E-02 SOD1 1
Cancer Quantity of papilloma 1.61E-02 GSTP1 1
Cancer Metastasis of cells 1.71E-02 NME1, PHB 2
Cancer Hepatocellular carcinoma 2.21E-02 NME1, SOD1, TPI1 3
Cancer Follicular adenoma 2.23E-02 GSTP1 1
Cancer Waldenstrom’s macroglobulinemia 2.26E-02 NME1,STIP1 2
Cancer Acute myeloid leukemia 2.31E-02 GSTP1, PSME1 2
Cancer Tumorigenesis of colon cancer cell lines 2.35E-02 SFN 1
Cancer Metastasis of cancer cells 2.96E-02 PHB 1
Cancer Infection of cervical cancer cell lines 3.05E-02 PSME2, RANBP1, STIP1 3
Cancer Growth of melanoma 3.08E-02 IL1RN 1
Cancer Metastasis of melanoma cell lines 3.20E-02 NME1 1
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(SODC) - were found to be in higher abundance in oral
cancer. Malignant cells are in general under increased
oxidative stress [6-8]. Thus, an increase of enzymes in-
volved in protection against oxidative stress may be a
mechanism to tolerate such stress.LGUL Catalyzes the conversion of hemimercaptal,
formed from methylglyoxal and glutathione, to S-
lactoylglutathione. Inhibitors of LGUL have been pro-
posed as possible antitumor agents that function by
inducing elevated levels of methylglyoxal in cancer
cells. Methylglyoxal has been shown to inhibit the
Figure 2 Top-scored molecular network with identified proteins implicated in cancer progression according to the IPA software.
Proteins in the network are represented by their gene symbols. Green colored shapes denote proteins with lower abundance in oral cancer cell
lines, while red colored shapes denote proteins with higher abundance in oral cancer cell lines A) molecule types, B) relationship types.
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has also been shown that LGUL inhibitors may also be a
drug resistance-reversing agent [10]. Increase of LGUL level
has been found in drug-resistant tumor cells and in invasive
ovarian cancer and breast cancer [11].
PRDX4 is involved in the redox regulation of the cell.
The level of peroxiredoxins (in particular PRDX3,
PRDX4 and PRDX5) has been shown to be increased in
cancer, suggesting the induction of PRDX as a response
to increased production of reactive oxygen species in
carcinomatous tissue [12].
GSTP1 conjugates reduced glutathione to a wide num-
ber of exogenous and endogenous hydrophobic electro-
philes. It plays an important role in the protection of
cells from the products of oxidative stress as well as
from several environmental carcinogens. The GSTP1
gene has been shown to be overexpressed in many hu-
man tumors [13].SODC destroys radicals which are normally produced
within the cells and which are toxic to biological sys-
tems. The level of SODC has been shown to increase in
a number of cancers [14-16].
Proteasome activator complex
Proteasome activator complex subunit 1 (PSME1) and
proteasome activator complex subunit 2 (PSME2) are
implicated in immunoproteasome assembly and is re-
quired for efficient antigen processing. IPA showed that
both proteins also interact and influence the function of
the 26 s and 20 s proteaseome. The proteasome is a
multicatalytic proteinase complex that is responsible for
the degradation of most intracellular proteins, including
proteins that are crucial to cell cycle regulation and
programmed cell death, or apoptosis. Targeting the pro-
teasome is being investigated as a useful anticancer strat-
egy [17]. PSME has also been proposed as a potential
Figure 3 Results of quantitative RT-PCR showing relative expressions of STMN1, 1433S, STIP1 and GSTP1. Total mRNA was extracted
from normal and oral cancer cell lines. Quantitative RT-PCR was then performed as described. A: Relative expression of STMN1, B: Relative expres-
sion of 1433S, C: Relative expression of STIP1, D: Relative expression of GSTP1. Relative intensities of all genes of interest were determined by
using β-actin as an internal standard. Results represent the mean ± SD for three experiments. *p < 0.05.
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teomics analysis showed a decrease in abundance of
these proteins, whereas the proteoasome activity is ex-
pected to increase in most cancers.Proteins with higher abundance in oral cancer cell line
Structural protein
Stathmin (STMN1) is involved in the regulation of the
microtubule filament system where it prevents the as-
sembly and promotes disassembly of microtubules. It
has been shown to be present at high levels in a variety
of human cancers and has been proposed as a potential
target in cancer therapies that disrupt the mitotic appar-
atus [19].Enzymes
A number of enzymes were found to be in higher abun-
dance in cancer cell lines. Triosephosphate isomerase
(TPIS) is a glycolysis enzyme that catalyzes the reversible
interconversion of triosephosphate isomers - dihydroxy-
acetone phosphate and D-glyceraldehyde 3-phosphate.
TPIS may be associated with cancer metastasis [20].
Nucleoside diphosphate kinase A (NDKA) plays a major
role in the synthesis of nucleoside triphosphates other than
ATP. NDKA is involved in cell proliferation, differentiation
and development, signal transduction, G protein-coupled
receptor endocytosis, and gene expression. It has been
shown to act as both a metastasis suppressor and promoter
in different tumors [21].
Ubiquitin-conjugating enzyme E2 N (UBE2N) mediates
the transcriptional activation of target genes. The increased
abundance of UBE2N and other ubiquitin conjugating
enzymes has been reported in various cancers [22-25].Gamma-glutamylcyclotransferase (GGCT) catalyzes the
formation of 5-oxoproline from gamma-glutamyl dipep-
tides and may play a significant role in glutathione homeo-
stasis. It induces the release of cytochrome c from the
mitochondria resulting in the induction of apoptosis.
GGCT may be associated in the induction of apoptosis in
leukemia U937 cells [26].
Proteasome subunit beta type 4 (PSB4) belongs to the
proteasome multicatalytic proteinase complex. This com-
plex is characterized by its ability to cleave peptides with
Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at
neutral or slightly basic pH.
Regulatory proteins
14-3-3 protein beta/alpha (1433B) is an adapter protein
implicated in the regulation of a large spectrum of both
general and specialized signaling pathways. 1433B binds
to a large number of partners, usually by recognition of
a phosphoserine or phosphothreonine motif. Binding
will generally result in the modulation of the activity of
the binding partner.
Prohibitin (PHB) has a role in regulating cell prolifera-
tion where it inhibits DNA synthesis. It has been shown
to be involved in a number of different cancers [27-30].
Stress-induced-phosphoprotein 1 (STIP1) mediates the
association of the molecular chaperones HSC70 and
HSP90. STIP1 has been shown to be secreted by, and in-
duces proliferation in glioma cells [31]. It has also been
implicated in a number of other cancers [32-34].
Interleukin-1 receptor antagonist protein (IL1RA) in-
hibits the activity of IL-1 by binding to its receptor. The
level of IL1RA has been shown to change in cancer [35-37].
Rho GDP-dissociation inhibitor 1 (GDIR) regulates the
GDP/GTP exchange reaction of the Rho proteins by
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subsequent binding of GTP to them. In cancer, GDIR
has been implicated in metastasis, mediation of cancer
cell motility and drug resistance [38-40].
Ran-specific GTPase-activating protein (RANG) inhibits
GTP exchange on Ran and plays an essential role in nuclear
transport by permitting RanGAP-mediated hydrolysis of
GTP on Ran complexed to karyopherin b [41].
Chaperones
Heat-shock protein beta-1 (HSPB1) is involved in stress re-
sistance and actin organization. Heat shock proteins (HSPs)
are a large and heterogeneous group of chaperones whose
synthesis can be induced by both physiological and patho-
logical conditions, such as heat shock, oxidative stress,
mitogenic signals, inflammation, infection and neoplastic
transformation. Although a number of HSPs has been
implicated with cancer, association of HSPB1has not been
reported.
Proteins with lower abundance in oral cancer cell line
Structural proteins
Tropomyosin alpha-3 chain (TPM3) binds to actin fila-
ments in muscle and non-muscle cells. In association
with the troponin omplex, it plays a central role in
the calcium dependent regulation of vertebrate striated
muscle contraction.
Myosin regulatory light chain-2 (ML12A) is a myosin
regulatory subunit that plays an important role in regu-
lation of both smooth muscle and non-muscle cell
contractile activity via its phosphorylation. ML12A has
been implicated in cytokinesis, receptor capping, and
cell locomotion. Phosphorylation of ML12A has been
shown to be critical in the invasiveness of metastatic
cancer cells [42].
Regulatory protein
14-3-3 protein sigma, also known as stratifin (1433S) is
an adapter protein implicated in the regulation of a wide
variety of both general and specialized signaling path-
ways. 1433S is a potential lymph node metastasis-related
protein in lung squamous carcinoma [43].
Chaperones
T-complex protein 1 subunit zeta-2 (TCPW) is a mo-
lecular chaperon that assists in the folding of proteins
upon ATP hydrolysis [44].
Others
Chloride intracellular channel protein 1 (CLIC1) is a
protein that can insert into cellular membranes to form
chloride ion channels. It has been shown that overex-
pression of CLIC1 promoted cell motility and invasion
of low metastasic cell lines (GBC-SD18L) in vitro, whileRNA interference of CLIC1 decreased cell motility and
invasive potency of highly metastasic cell lines (GBC-
SD18H) in vitro, suggesting that CLIC1 may play an im-
portant role in metastasis of gallbladder carcinoma [45].
CLIC1 has also been proposed as a potential biomarker
[46,47] and therapeutic target [48] for cancer.
Assessment of mRNA transcript
Quantitative real-time PCR was performed to assess the
mRNA expression of four proteins - STMN1, 1433S, STIP1
and GSTP1. These proteins were selected due the marked
difference in their abundance and/or possible involvement
in cancer. They also represented proteins from various
functional categories. The mRNA expression of all four
genes was found to correlate with its corresponding protein
abundance. However, only 1433S and STIP1 was found to
be statistically significant (Figure 3). This suggested that
these proteins may be regulated at the mRNA level.
Conclusions
We have showed that a comparative study of the oral
cancer cell line proteome may identify cancer associated
proteins. IPA predicted that at least 18 of these proteins
were associated with cancer development and progres-
sion. At least two identified proteins (CLIC1 and PSME)
have previously been proposed as potential biomarkers
for cancer. Two groups of proteins (detoxification en-
zymes and proteasome activator complex) appeared to
show coordinate change in protein abundance. Taken to-
gether, these results has demonstrated the potential of
this type of study as an alternative to directly analyzing
tissue samples in identifying cancer associated proteins.
This study can be further extended by investigating the
presence/absence of these proteins in tissue samples.
Methods
Establishment of cell cultures
This project was approved by the Medical Ethics Commit-
tee, Faculty of Dentistry, University of Malaya and endorsed
by the Ministry of Health, Malaysia (DFOP1006/0041[P]).
Normal tissues were derived from surgically resected tissue
specimens from different impacted tooth patients. Cancer-
ous tissues were derived from surgically resected tissue
specimens from three different oral squamous cell carcin-
oma patients. Sample collection was performed at the Fac-
ulty of Dentistry and University Malaya Medical Centre,
Kuala Lumpur Hospital and Tengku Ampuan Rahimah
Hospital. All tissues were acquired after written informed
consent was obtained from the patients. The oral cancer
cell lines and primary cultures were derived from squamous
cells and were originated from the same anatomic site
(gum). Cell cultures were established as previously de-
scribed [49,50].
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Cells were grown to confluence. Following trypsiniza-
tion, cells were pelleted and washed 3× with PBS. The
cells were then lysed by repeated freeze thawing in ex-
traction buffer (5 M Urea, 2 M Thiourea, 2% SB3-10
and 2% CHAPS). Protein concentration was deter-
mined by Bradford assay using Bovine Serum Albumin
as standard according to the manufacturer’s instruc-
tion (Bio-Rad Laboratories).
Two-Dimensional Gel Electrophoresis (2DE)
For each cell line/primary culture, 2DE was performed
in triplicate on protein samples extracted from three dif-
ferent passages of growth. Isoelectric focusing for 2DE
was performed using an IPGphor system (Amersham
Biosciences) according to the manufacturer’s protocol.
Briefly, IPG strips (24 cm Immobiline IPG Drystrip
pH 4–7) were rehydrated overnight using 450 μl/strip urea
rehydration stock solution (8 M Urea, 2% w/v CHAPS,
0.5% v/v Pharmalyte/IPG Buffer pH3-10, 1% trace bromo-
phenol blue) without containing the sample. Protein ex-
tracts were solubilized in 80 μl sample lysis buffer (8 M
Urea, 4% w/v CHAPS, 40 mM Tris, 65 mM DTT, 1% trace
bromophenol blue) and loaded into the loading cup just be-
fore running. A total of 80 μg protein was loaded for analyt-
ical gels and 160 μg loaded for preparative gels. Isoelectric
focusing was performed for 60 kVh with running condi-
tions as follows: 500 V: 1 hour, 1000 V: 1 hour, 1000 V: 3
hours and finally a constant 8000 V at 20°C.
For the second dimension, the IPG strips were first equil-
ibrated in 10 ml of SDS equilibration buffer (6 M Urea,
75 mM Tris–HCl pH8.8, 87% w/w glycerol, 2% SDS, 1%
trace bromophenol blue) containing 1% DTT for 10 mi-
nutes, followed by a second equilibration for 10 minutes in
the same equlibration buffer containing 2.5% Iodoaceta-
mide. Equilibrated strips were then placed on 11% SDS-
Polyacrylamide gel and enclosed with 0.5% agarose gel.
Second dimension electrophoresis of reduced and alkylated
samples was carried out using an Ettan Dalt twelve system
(GE Healthcare). Electrophoresis was initially performed at
2 W for 45 minutes, followed by 110 W until the bromo-
phenol blue dye reached the bottom edge of the gel.
Protein spots were visualized using protocols described in
the PlusOne™ Silver staining kit (GE Healthcare). The
complete protocol was followed for analytical gels. For pre-
parative gels, a modified protocol was used. Glutaraldehyde
was omitted from the sensitization step and formaldehyde
omitted from the silver reaction step [51].
Gel image analysis
Following 2DE and silver staining, gels were scanned
(Image Scanner III, GE Healthcare) and protein profiles
compared using the ImageMaster Platinum 7.0 software
(GE Healthcare). Protein spots were normalized usingpercentage volume. Statistical analysis for the compari-
son of protein abundance between the groups was per-
formed by Student’s t-test. Only protein spots with fold
difference > 1.4 and p < 0.05 were considered to have sig-
nificantly changed in abundance.
Tryptic digestion
Protein spots were excised and in-gel digested with tryp-
sin (Promega) for mass spectrometric identification ac-
cording to published protocols [52-54].
MALDI-TOF/TOF mass spectrometry analysis and
database searching
Protein identification was performed as previously de-
scribed using a MALDI-TOF mass spectrometer (ABI 4800
Plus, Applied Biosystems) [55,56].
Bioinformatics
Categorization of protein function was determined based
on Swiss-Prot/TrEMBL database search. Ingenuity Pathway
Analysis (IPA, www.ingenuity.com) was used to determine
the localization of identified proteins and their participation
in molecular networks involved in carcinogenesis according
to the well-established Ingenuity Knowledge Base. Details
regarding proteins that were different in abundance were
exported to the IPA software. Each protein identifier was
then mapped to its corresponding protein object and was
overlaid onto a global molecular network developed from
information contained in the Ingenuity Knowledge Base.
Protein networks were then algorithmically generated based
on their connectivity. A Right-tailed Fischer’s exact test was
used to calculate a p-value indicating the probability that
each biological function assigned to the network is not due
to chance alone.
Real-time PCR (RTPCR)
All experiments were performed according to manufac-
turers’ instructions. Total mRNA was extracted from cell
pellets using RNAqueous®-4PCR Kit (Ambion). High Cap-
acity cDNA Reverse Transcription kit (Applied Biosystems)
was used to reverse transcribe total mRNA into cDNA
templates. RTPCR was performed by either Taqman® Gene
Expression Assay or Fast Sybr Green (Applied Biosystems).
Primers were either designed using the Primer3 software
or were based on literature and PrimerBank [57,58]. The
specificity of primers was examined using NCBI primer-
Blast (www.ncbi.nlm.nih.gov/tools/primer-blast/). All PCR
reactions were performed using the StepOnePlus Real-
Time PCR instrument (Applied Biosystems). PCR condi-
tions were defined according to the manufacturer’s
recommended parameters. Gene expression levels were
comparatively analyzed using StepOne software v2.2. Raw
data from the experiments were recalculated as a mean
expression level of cancer and normal groups to generalize
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dent’s unpaired t-test was then performed to determine
the significance of the results.
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